Peptide Therapy for Stroke Rehabilitation: A Comprehensive Clinical Review

Medically reviewed by Dr. Sarah Chen, PharmD, BCPS

## Peptide Therapy for Stroke Rehabilitation: A Comprehensive Clinical Review Stroke is a major cause of death and disability, and effective therapie...

Peptide Therapy for Stroke Rehabilitation: A Comprehensive Clinical Review

Stroke is a major cause of death and disability, and effective therapies for promoting recovery are urgently needed. Peptide therapy has emerged as a promising area of research, with several peptides showing potential to enhance stroke rehabilitation by targeting various pathological processes, including neuroinflammation, excitotoxicity, oxidative stress, and impaired neurogenesis. This review provides a comprehensive overview of the clinical evidence for peptide therapy in stroke recovery, delving into mechanisms of action, practical considerations, and future directions.

Peptides with Neuroprotective and Neurorestorative Properties

A number of peptides have been investigated for their ability to protect the brain from damage after a stroke and to promote repair and recovery. These include:

Cerebrolysin: This peptide mixture, derived from porcine brain proteins, has been studied extensively in stroke and has been shown to improve neurological outcomes and cognitive function. Its complex composition includes various neurotrophic factors and active peptide fragments that mimic the action of endogenous neurotrophic factors. Cerebrolysin's mechanisms of action include neuroprotection (reducing excitotoxicity and oxidative stress), neurotrophic support (promoting neuronal survival and differentiation), and neurorestoration (enhancing synaptogenesis and angiogenesis) [1, 4]. Clinical trials, particularly in acute ischemic stroke, have demonstrated its efficacy in improving global neurological deficit and functional recovery, with meta-analyses supporting its beneficial effects [5, 6].

BPC-157: Known for its regenerative properties, Body Protection Compound-157 (BPC-157) is a synthetic peptide derived from human gastric juice. In the context of stroke, BPC-157 may help to reduce inflammation, promote angiogenesis, and protect neurons from damage [7]. Preclinical studies suggest it can mitigate brain damage following ischemic stroke by modulating nitric oxide pathways, enhancing endothelial cell migration, and promoting the survival of various cell types [8]. While human trials for stroke are limited, its broad regenerative capabilities make it a compelling candidate for further investigation.

  • Semax: This nootropic peptide, an analog of ACTH (adrenocorticotropic hormone) fragment, has been shown to have neuroprotective effects and may improve cognitive function after a stroke. Semax influences the expression of neurotrophic factors, modulates neurotransmitter systems (dopamine, serotonin), and exhibits anti-inflammatory and antioxidant properties [9]. It has been used clinically in Russia and Ukraine for various neurological conditions, including stroke, where it has demonstrated efficacy in improving cognitive performance and neurological deficits [10].

    • Peptides Targeting Specific Post-Stroke Complications

    In addition to general neuroprotective and neurorestorative effects, some peptides may be useful for targeting specific complications of stroke, such as cognitive impairment, motor deficits, and the inflammatory cascade.

    | Peptide | Target | Potential Benefit in Stroke Rehabilitation | Mechanism of Action (Expanded)